Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase

Journal of Diabetes Science and Technology

Volumn 6, Issue 4, 2012, Pages 764-772

  Muchmore, Douglas B ^a   Vaughn, Daniel E ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Hyaluronidase; Recombinant human hyaluronidase; Ultrafast insulin

Indexed keywords

GLUCOSE; INSULIN ASPART; INSULIN LISPRO; RECOMBINANT HYALURONIDASE; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; EXCIPIENT; HISTONE ACETYLTRANSFERASE; HYALURONOGLUCOSAMINIDASE; MGEA5 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR ANTIGEN;

ADJUVANT THERAPY; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; IMMUNOGENICITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PUNCH BIOPSY; TEST MEAL; TIME TO MAXIMUM PLASMA CONCENTRATION; ABSORPTION; ACCELERATION; ADULT; ARTICLE; CHEMISTRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM; DRUG EFFECT; INSULIN INFUSION; MALE; METHODOLOGY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ABSORPTION; ACCELERATION; ADULT; ANTIGENS, NEOPLASM; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; EXCIPIENTS; HISTONE ACETYLTRANSFERASES; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN INFUSION SYSTEMS; INSULIN LISPRO; INSULIN, SHORT-ACTING; MALE; POSTPRANDIAL PERIOD; RECOMBINANT PROTEINS;

EID: 84873115674     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600405     Document Type: Conference Paper

References (31)

1. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther. 1995;58(4):459-69.
2. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 201. Epub ahead of print.
3. Van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13(6):607-14.
4. Hompesch M, Muchmore DB, Morrow L, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care. 2011;34(3):666-8.
5. Hompesch M, Muchmore DB, Morrow L, Ludington E, Vaughn DE. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. Diabetes Technol Ther. 2012;14(3):218-24.
6. Heinemann L, Hompesch M, Flacke F, Simms P, Pohl R, Albus K, Pfützner A, Steiner S. Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin. J Diabetes Sci Technol. 2011;5(3):681-6.
7. Juvenile Diabetes Research Foundation. Glucose control therapy research strategy. http://www.jdrf.org/index.cfm?page-id=116211. Accessed February 22, 2012.
8. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114(2):230-41. (Pubitemid 44291844)
9. Duran-Reynals F. The effect of extracts of certain organs from normal and immunized animals on the infecting power of vaccine virus. J Exp Med. 1929;50(3):327-40.
10. Hoffman DC, Duran-Reynals F. The mechanism of enhancement of infections by testicle extract. Science. 1930;72(1872):508.
11. Duthie ES, Chain EA. A mucolytic enzyme in testes extracts. Nature. 1939;144:977-8.
12. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427-40. (Pubitemid 47249140)
13. Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9(11):3052-64.
14. Reed RK, Laurent UB, Fraser JR, Laurent TC. Removal rate of [3H]hyaluronan injected subcutaneously in rabbits. Am J Physiol. 1990;259(2 Pt 2):H532-5. (Pubitemid 20259430)
15. Laurent UB, Dahl LB, Reed RK. Catabolism of hyaluronan in rabbit skin takes place locally, in lymph nodes and liver. Exp Physiol. 1991;76(5):695-703.
16. Tyndel M. Hyaluronidase as an adjuvant in insulin shock therapy. J Am Med Assoc. 1956;162(1):32-4.
17. Søeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci. 2009;36(1):78-90.
18. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11(6):345-52.
19. Vaughn DE, Muchmore DB. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion. Endocr Pract. 2011;17(6):914-21.
20. Morrow L, Muchmore DB, Hompesch M, Ludington E, Vaughn DE. Human hyaluronidase coinjection accelerates insulin pharmacokinetics and glucodynamics of 3 rapid insulin analogs. American Diabetes Association. 70th Scientific Sessions (2010). http://professional.diabetes.org/Abstracts-Display.aspx?TYP= 1&CID=79294. Accessed June 22, 2012.
21. Vaughn D, Gee L, Ludington E, Muchmore D. Improved dose proportionality of insulin lispro injected with hyaluronidase. J Diabetes Sci Technol. 2010;4(2):484-7, A176.
22. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 2011;13(10):1039-45.
23. Muchmore DB, Morrow L, Hompesch M, Vaughn D. Improved consistency of pharmacokinetic and glucodynamic responses using recombinant human hyaluronidase pretreatment with continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Diabetes Sci Technol. 2012;6(2):462-5, A117.
24. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Stefen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32(2):240-4.
25. Hylenex recombinant product package insert. March 20, 2012.
26. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J Infus Nurs. 2007;30(5):293-9. (Pubitemid 47585290)
27. Chowpongpang S, Shin HS, Kim EK. Cloning and characterization of the bovine testicular PH-20 hyaluronidase core domain. Biotechnol Lett. 2004;26(15):1247-52. (Pubitemid 40938277)
28. Buse JB, Garg SK, Skyler JS, Vaughn DE, Muchmore DB. Comparison of human hyaluronidase + recombinant human insulin (RHI) vs. insulin lispro in a basal-bolus regimen in patients with type 1 diabetes (T1DM). American Diabetes Association 71st Scientific Sessions (2011). http://professional.diabetes.org/ Abstracts-Display.aspx?TYP=1&CID=86497. Accessed June 22, 2012.
29. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(19):1231-9.
30. Muchmore DB, Vaughn DE. Review of the mechanism of action and clinical eficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol. 2010;4(2):419-28.
31. Clausen TS, Kaastrup P, Stallknecht B. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther. 2009;11(9):575-80.